Hycor Biomedical Expands Board of Directors to Support Growth in Key Areas
Published: May 16, 2011
GARDEN GROVE, Calif., May 16, 2011 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets, together with owner Linden, LLC, today announced the appointments of Vijay Aggarwal, Ph.D. and James Koziarz, Ph.D., to its Board of Directors as part of its global growth strategy.
"We are thrilled to welcome Drs. Aggarwal and Koziarz to the HYCOR team and are confident they will have meaningful impact in areas critical for the company's continued growth," said Richard Novak, Chairman of HYCOR's Board of Directors, and Operating Partner at Linden, LLC. "Both of these gentlemen have extensive backgrounds in clinical diagnostics for market leading companies, and we are certain that HYCOR will benefit from their guidance in the near and long term."
Dr. Aggarwal brings more than 30 years of experience and leadership in the pharmaceutical and diagnostics industries, having served in senior management positions for a number of leading companies, including Quest Diagnostics, IBT Laboratories and SmithKline Beecham. As Director, Dr. Aggarwal will support the HYCOR management team in a variety of capacities with a particular focus on channel development in clinical laboratories.
Dr. Koziarz joins HYCOR's Board after a distinguished 25 year career at Abbott Laboratories, where he held several senior management and executive positions, including Corporate Vice President for Diagnostic Products Research & Development. Dr. Koziarz is also an active advisor to several leading life sciences companies. As Director, Dr. Koziarz will support the HYCOR management team on next generation assay and platform development strategies for global customers.
"We are pleased to have the opportunity to partner with these two leaders in clinical diagnostics and are confident it will benefit HYCOR, the healthcare professionals and patients our products serve," said Dick Aderman, CEO, HYCOR. "Our executive team has begun working with each of them on key initiatives currently underway and we look forward to the value they will bring to our business."
HYCOR's CEO, Dick Aderman, also brings extensive leadership in the clinical diagnostics arena, having spent more than 30 years serving in senior management positions for a number of clinical diagnostic companies, including Roche Diagnostics Corporation, Boehringer Mannheim Corporation and Dade International.
About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC, KOVA® and AUTOSTAT brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.hycorbiomedical.com.
About Linden LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden's portfolio includes BarrierSafe Solutions International, Behavioral Centers of America, Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and Ranir. For additional information, please visit www.lindenllc.com.
SOURCE HYCOR Biomedical, Inc.